The angiotensin-converting enzyme insertion/deletion polymorphism and serum levels of angiotensin-converting enzyme in venous thromboembolism

Cihan Ay; Peter Bencur; Rainer Vormittag; Thomas Sailer; Christof Jungbauer; Thomas Vukovich; Christine Mannhalter; Ingrid Pabinger

doi:10.1160/TH07-03-0209

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2007; 98(04): 777-782
DOI: 10.1160/TH07-03-0209

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

The angiotensin-converting enzyme insertion/deletion polymorphism and serum levels of angiotensin-converting enzyme in venous thromboembolism

Data from a case control study

Cihan Ay

¹Division of Haematology and Haemostaseology, Department of Internal Medicine I, Medical University Vienna, Austria

,

Peter Bencur

²Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Vienna, Austria

,

Rainer Vormittag

¹Division of Haematology and Haemostaseology, Department of Internal Medicine I, Medical University Vienna, Austria

,

Thomas Sailer

¹Division of Haematology and Haemostaseology, Department of Internal Medicine I, Medical University Vienna, Austria

,

Christof Jungbauer

³Austrian Red Cross, Blood Donation Centre for Vienna, Lower Austria and Burgenland, Austria

,

Thomas Vukovich

²Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Vienna, Austria

,

Christine Mannhalter

²Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Vienna, Austria

,

Ingrid Pabinger

¹Division of Haematology and Haemostaseology, Department of Internal Medicine I, Medical University Vienna, Austria

› Author Affiliations

Abstract

Summary

The angiotensin-converting enzyme (ACE) has been suggested to affect blood coagulation and fibrinolysis. Results from literature on the role of the frequent insertion/deletion (I/D) polymorphism in the ACE gene in venous thromboembolism (VTE) are controversial. Only limited data on ACE serum levels in VTE exist. We determined the ACE I/D polymorphism by genotyping and ACE serum levels by an enzymatic assay in 100 high-risk patients with objectively confirmed recurrent VTE and at least one event of an unprovoked deep venous thrombosis or pulmonary embolism. One hundred twenty-five age- and sex-matched healthy individuals served as controls. ACE genotype frequencies were not significantly different between patients (DD: 26.0%,ID: 52.0%, II: 22.0%) and controls (DD: 29.6%, ID: 44.8%, II: 25.6%; p=0.56). Neither individuals with ACE DD genotype nor those with ACE ID genotype had a higher risk for VTE in comparison to those with ACE II genotype (odds ratio and [95% confidence interval]: 1.0 [0.5–2.1] and 1.4 [0.7–2.6], respectively). Serum ACE levels (U/l) did not differ between patients (median = 25.25, 25th –75th percentile: 20.20–33.70) and controls (24.20, 17.85–34.50, p=0.49). In the total population involved in the study the ACE DD genotype (n=63: 36.00 [26.40–43.00]) was associated with higher ACE levels than the ACE ID genotype (n=108: 24.10 [19.80–31.48], p<0.001) and the ACE II genotype (n=54: 19.35 [15.00–22.95], p<0.001). In conclusion, we found a significant association of the ACE I/D polymorphism with ACE serum levels. However, neither the serum levels nor the I/D genotype were associated with VTE.

Keywords

Angiotensin-converting enzyme - insertion/deletion polymorphism - deep venous thrombosis - pulmonary embolism - venous thromboembolism

Full Text

References

References
1 Nishimura H, Tsuji H, Masuda H. et al. The effects of angiotensin metabolites on the regulation of coagulation and fibrinolysis in cultured rat aortic endothelial cells. Thromb Haemost 1999; 82: 1516-1521.
2 Vaughan DE. The renin-angiotensin system and fibrinolysis. Am J Cardiol 1997; 79: 12-16.
3 Hayes LW, Goguen CA, Ching SF. et al. Angiotensin- converting enzyme: accumulation in medium from cultured endothelial cells. Biochem Biophys Res Commun 1978; 82: 1147-1153.
4 Beneteau-Burnat B, Baudin B. Angiotensin-converting enzyme: clinical applications and laboratory investigations on serum and other biological fluids. Crit Rev Clin Lab Sci 1991; 28: 337-3356.
5 Rigat B, Hubert C, Corvol P. et al. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992; 20: 1433.
6 Rigat B, Hubert C, Alhenc-Gelas F. et al. An insertion/ deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
7 Tiret L, Rigat B, Visvikis S. et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992; 51: 197-205.
8 Okumus G, Arseven O. Insertion/deletion polymorphism of the angiotensin-converting enzyme gene: really a risk factor for venous thromboembolism?. Thromb Haemost 2003; 90: 766-767.
9 Philipp CS, Dilley A, Saidi P. et al. Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty. Thromb Haemost 1998; 80: 869-873.
10 von Depka M, Czwalinna A, Wermes C. et al. The deletion polymorphism in the angiotensin-converting enzyme gene is a moderate risk factor for venous thromboembolism. Thromb Haemost 2003; 89: 847-852.
11 Lu Y, Hui R, Zhao Y. Insertion/deletion polymorphsim of the angiotensin I converting enzyme gene and pulmonary thromboembolism in Chinese population. Zhonghua Jie He He Hu Xi Za Zhi 2001; 24: 265-268.
12 Fatini C, Gensini F, Sticchi E. et al. ACE DD genotype: an independent predisposition factor to venous thromboembolism. Eur J Clin Invest 2003; 33: 642-647.
13 Jackson A, Brown K, Langdown J. et al. Effect of the angiotensin-converting enzyme gene deletion polymorphism on the risk of venous thromboembolism. Br J Haematol 2000; 111: 562-564.
14 Wells PS, Rodger MA, Forgie MA. et al. The ACE D/D genotype is protective against the development of idiopathic deep vein thrombosis and pulmonary embolism. Thromb Haemost 2003; 90: 829-834.
15 Buddingh EP, Van Hylckama Vlieg A, Rosendaal FR. The angiotensin-converting enzyme gene insertion/ deletion polymorphism: insufficient evidence for a role in deep venous thrombosis. J Thromb Haemost 2005; 3: 403-404.
16 Koppel H, Renner W, Gugl A. et al. The angiotensin- converting-enzyme insertion/deletion polymorphism is not related to venous thrombosis. Thromb Haemost 2004; 91: 76-79.
17 Gonzalez Ordonez AJ, Fernandez Carreira JM, Medina Rodriguez JM. et al. Risk of venous thromboembolism associated with the insertion/deletion polymorphism in the angiotensin-converting enzyme gene. Blood Coagul Fibrinolysis 2000; 11: 485-490.
18 Pabinger I, Grafenhofer H, Kaider A. et al. Preeclampsia and fetal loss in women with a history of venous thromboembolism. Arterioscler Thromb Vasc Biol 2001; 21: 874-879.
19 Vormittag R, Vukovich T, Schonauer V. et al. Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism. Thromb Haemost 2005; 93: 488-493.
20 Vormittag R, Hsieh K, Kaider A. et al. Interleukin-6 and interleukin-6 promoter polymorphism (-174) G > C in patients with spontaneous venous thromboembolism. Thromb Haemost 2006; 95: 802-806.
21 Dilley A, Austin H, Hooper WC. et al. Relation of three genetic traits to venous thrombosis in an African- American population. Am J Epidemiol 1998; 147: 30-35.
22 Della Valle CJ, Issack PS, Baitner A. et al. The relationship of the factor V Leiden mutation or the deletion- deletion polymorphism of the angiotensin converting enzyme to postoperative thromboembolic events following total joint arthroplasty. BMC Musculoskelet Disord 2001; 2: 1.
23 Ekim N, Oguzulgen IK, Demir N. et al. The role of angiotensin-converting enzyme gene polymorphism in pulmonary thromboembolism. Thromb Haemost 2004; 92: 432-433.
24 Dilley A, Austin H, El-Jamil M. et al. Genetic factors associated with thrombosis in pregnancy in a United States population. Am J Obstet Gynecol 2000; 183: 1271-1277.
25 Munoz Mendez J, Alfajeme Michavila I, Hernandez Borge J. et al. Angiotensin-converting enzyme in pulmonary thromboembolism as a marker of vascular lesion. Rev Clin Esp 1997; 197: 84-91.
26 Drouet L, Baudin B, Baumann FC. et al. Serum angiotensin- converting enzyme: an endothelial cell marker. Application to thromboembolic pathology. J Lab Clin Med 1988; 112: 450-457.
27 Cidl K, Strelcova L, Znojil V. et al. Angiotensin I-converting enzyme (ACE) polymorphism and ABO blood groups as factors codetermining plasma ACE activity. Exp Hematol 1996; 24: 790-794.
28 King MJ. Blood group antigens on human erythrocytes- distribution, structure and possible functions. Biochim Biophys Acta 1994; 1197: 15-44.